Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Antibody; HTLV-I

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86687 refers to the laboratory test for antibodies to human T-lymphotropic virus type I (HTLV-I). This test is crucial for diagnosing infections caused by HTLV-I and HTLV-II, which are both sexually transmitted diseases. These viruses can also be transmitted through unscreened blood transfusions, sharing of needles, and from mother to child during pregnancy or breastfeeding. HTLV-I is particularly significant as it is associated with serious health conditions, including adult T-cell leukemia and various disorders affecting bone marrow and blood cells. The human immunodeficiency virus (HIV), which is also tested for in conjunction with HTLV, compromises the immune system by targeting T cells or CD4 cells, leading to a reduced ability to combat infections. The final stage of HIV infection is known as acquired immunodeficiency syndrome (AIDS). The testing for HTLV-I and HTLV-II antibodies is typically performed using an enzyme immunosorbent assay (EIA), which detects the presence of these antibodies in human serum or plasma. If the initial EIA test yields a positive result, a confirmatory test is conducted using immunoblot or Western blot techniques, which are reported under CPT® Code 86689. The Western blot method involves separating proteins by size and shape through gel electrophoresis, followed by transferring these proteins onto a membrane where specific antibodies can bind, allowing for the detection of the viruses. This comprehensive testing process is essential for accurate diagnosis and management of infections related to HTLV and HIV.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The antibody test for HTLV-I (CPT® Code 86687) is indicated for the following conditions:

  • Screening for HTLV-I Infection This test is performed to identify individuals who may be infected with HTLV-I, particularly in populations at higher risk for this virus.
  • Diagnosis of HTLV-I Related Disorders The test aids in diagnosing conditions associated with HTLV-I, such as adult T-cell leukemia and other hematological disorders.
  • Assessment of Blood Donors Blood banks may utilize this test to screen donated blood for HTLV-I antibodies to prevent transmission through transfusions.

2. Procedure

The procedure for testing antibodies to HTLV-I involves several key steps:

  • Sample Collection A blood sample is collected from the patient, typically through venipuncture, and is then processed to obtain serum or plasma for testing.
  • Enzyme Immunosorbent Assay (EIA) The serum or plasma sample is subjected to an enzyme immunosorbent assay (EIA), which is designed to detect antibodies specific to HTLV-I. This assay utilizes test kits that contain antigens related to the virus.
  • Interpretation of EIA Results If the EIA test result is positive, indicating the presence of antibodies to HTLV-I, a confirmatory test is required to validate the result.
  • Confirmatory Testing The confirmatory test is performed using immunoblot or Western blot techniques. In this step, the sample proteins are separated by gel electrophoresis and then transferred onto a membrane.
  • Detection of Antibodies The patient sample is added to the membrane, allowing any antibodies present to bind to the specific proteins. Labeled antibodies are then used to detect the presence of HTLV-I antibodies.
  • Comparison with Controls The results of the test are compared with known negative and positive control samples to determine the presence of HTLV-I antibodies accurately.

3. Post-Procedure

After the procedure, the patient may be advised on the next steps based on the test results. If the EIA test is positive, further confirmatory testing will be conducted, and the patient should be informed about the implications of a positive result, including potential follow-up care and counseling. It is essential to ensure that patients understand the significance of the test results and the importance of follow-up testing, especially in the context of potential transmission risks associated with HTLV-I and related viruses. Additionally, healthcare providers should discuss any necessary precautions or lifestyle changes that may be recommended based on the patient's results.

Short Descr HTLV-I ANTIBODY
Medium Descr ANTIBODY HTLV-I
Long Descr Antibody; HTLV-I
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 235 - Other Laboratory
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
Date
Action
Notes
1990-01-01 Added First appearance in code book in 1990.
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"